Contact

 

Prof. Dr. Rienk Offringa
Phone: +49 6221-423140

E-mail: r.offringa@dkfz.de

Improving the treatment ...

 

of pancreatic cancer by combining cytotoxic and immunotherapeutic strategies.

Molecular Oncology of Gastrointestinal Tumors

DKFZ
 
 
 

2010 – 2013

  • Wilson NS, et al.  2011. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19: 101-13
  • Burington B, et al.  2011. CD40 pathway activation status predicts the anti-tumor activity of CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med 3(74):74ra22
  • Oliveira CC, et al.  2010. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med 207: 207-2
  • Offringa R. (2009). Antigen choice in adoptive Tcell therapy of cancer. Curr Opin Immunol, 21, 190–199.
  • Bos R, et al. (2008). Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res, 68, 8446–8455. van Hall T, et al. (2006). Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med, 12, 417–424.